Financial Performance - Revenues reached ₹8,545 Cr, showing an 11% YoY growth[9] - EBITDA stood at ₹2,278 Cr with a margin of 26.7%[9] - Profit Before Tax (PBT) was ₹1,905 Cr, representing 22%[9] - Profit After Tax (PAT) amounted to ₹1,418 Cr, which is 17%[9] Segment Performance - Global Generics contributed ₹7,562 Cr, with a 10% YoY increase[13] - North America generated ₹3,412 Cr in revenue, up by 11% YoY[13] - India's revenue was ₹1,471 Cr, marking an 11% YoY growth[13] - Europe reported revenue of ₹1,274 Cr, a significant 142% YoY increase, including revenues from the acquired NRT business[13] - Pharmaceutical Services & Active Ingredients (PSAI) achieved ₹818 Cr in revenue, a 7% YoY increase[13] - Emerging Markets reached ₹1,404 Cr in revenue, showing an 18% YoY increase[13] Financial Position - Net Cash surplus at ₹2,922 Cr as of June 30, 2025[11, 22]

Group 1 - Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies [1][3] - The company is participating in the H.C. Wainwright "HCW@Home" Series, with a fireside chat scheduled for July 30, 2025 [2] - Nkarta is advancing allogeneic, off-the-shelf NK cell therapies aimed at treating autoimmune diseases, utilizing a combination of cell expansion, cryopreservation, and CRISPR-based genome engineering [3] Group 2 - The event will be available via a simultaneous webcast on Nkarta's website, with a replay accessible for approximately 90 days [2] - Nkarta's approach is designed for deep therapeutic activity and broad access in outpatient treatment settings [3] - For further information, Nkarta's media and investor contact is Nadir Mahmood [4]

- By examining over 100 unique variants associated with the CASR gene causative of ADH1, the average frequency of gain-of-function CASR variants was ~3.7 per 100,000, closely aligned to previously published estimates1 (3.9 per 100,000), which equates to approximately 25,000 carriers of ADH1-causing variants in the US and EU - Only ~20% of individuals with genetic variants linked to ADH1 were found to have an established diagnosis, highlighting a major gap in disease recognition and care - Nine novel gain-of ...

Payment is part of $17.6 million award granted for leptomeningeal cancer targeted radiotherapeutic development programHOUSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the Company received notice of an advance payment of $1.6 million from the Cancer Prevention and Research Institute of ...

DUBLIN and BRIDGEWATER, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2025 results and recent strategic steps followed by Q&A on Wednesday, July 30th, 2025, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2025 financial results in the pre-market hours on Ju ...

A wave of upgraded guidance from major U.S. companies is reshaping the outlook for the rest of 2025, and analysts are responding in kind. Strong Q2 earnings results have prompted several high-profile firms to lift their full-year forecasts, triggering a flurry of price target hikes across Wall Street. From streaming to finance to fashion, these upgrades aren't just routine adjustments—they're signaling confidence in continued momentum, even as markets remain cautious. Let’s take a look at four companies tha ...

- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (tr ...

PLEASANTON, Calif., July 23, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data across more than 100 countries with Veeva OpenData and Veeva Network. Accurate and comprehensive customer reference data from OpenData will equip Boehringer Ingelheim's teams with the insights needed to engage healthcare professionals (HCPs) with relevant information, while laying the data foundation to scale AI. "Extending our trusted ...

The SPEAR Study Group was established in response to multiple independent case reports and reported case series from across the U.S. suggesting symptom improvement / remission of Long COVID in individuals with Long COVID following administration of PEMGARDA® (pemivibart), a broadly neutralizing monoclonal antibody currently authorized by the U.S. FDA for the prevention of COVID-19 in certain immunocompromised individuals. PEMGARDA is not authorized for the treatment of Long COVID. Early anecdotal evidence s ...

Core Insights - Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, with a pipeline that includes seven programs, three of which are in clinical stages [1][3] - The company will host a conference call and live webcast on August 6, 2025, to report its second quarter 2025 financial results and provide a business update [1][2] Company Overview - Neumora's mission is to address the global brain disease crisis by innovating the development of treatments for neuropsychiatric disorders and neurodegenerative diseases [3] - The therapeutic pipeline targets novel mechanisms of action and is supported by a suite of translational, clinical, and computational tools aimed at enabling precision medicine [3]